Major Depressive Disorder
Conditions
Keywords
Major depressive disorder, Antidepressants, Weight gain, Metabolic syndromes
Brief summary
Since antidepressants and antipsychotics have common receptorial mechanisms of action (H1 antagonism, 5HT2 antagonism), the impact of antidepressants in terms of metabolic syndromes is a matter of concern. The main objective of this study is to assess the differential impact of antidepressants in terms of weight gain and metabolic syndromes.
Detailed description
Since antidepressants and antipsychotics have common receptorial mechanisms of action (H1 antagonism, 5HT2 antagonism), the impact of antidepressants in terms of metabolic syndromes is a matter of concern. The main objective of this study is to assess the differential impact of antidepressants in terms of weight gain and metabolic syndromes. Prospective 6-month naturalistic cohort study, comparing 4 classes of antidepressants (SSRIs, SNRIs, TCAs and others) to a control group (ECT and r-TMS), in 600 patients with a major depressive disorder requiring the beginning of either antidepressant or ECT/r-TMS treatment.
Interventions
DRUGTricyclic antidepressants
antidepressant version medical dispositive
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age : 18-70 * Current major depressive episode (Major depressive disorder) based on the MINI interview * HAM-D \>18 * Requiring either antidepressant treatment, either ECT or r-TMS (as assessed by the clinician) * Signed informed consent
Exclusion criteria
* Bipolar disorder (DSM-IV), Psychotic disorder (DSM-IV), Substance abuse or dependence (DSM-IV) * Normothymic treatment * Antipsychotic treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Definition criteria of the metabolic syndromes: Weight and waist circumference Systolic and diastolic blood pressure Glycemia Triglyceridemia Cholesterolemia Insulinemia | at Months 0, 1, 3, 6 |
Secondary
| Measure | Time frame |
|---|---|
| Antidepressant efficacy (HAM-D, quickIDS-C, quickIDS-SR, CGI) | at Months 0, 1, 3, 6 |
Countries
France
Outcome results
None listed